Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb662 in advanced solid tumors
NCT05996445Phase 1Terminated
- Sponsor
- Xencor
- Start
- Jul 2023
- Primary completion
- May 2024
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of XmAb662 in solid tumor (2 arms), sponsored by Xencor. Primary endpoints: Incidence of Dose-Limiting Toxicities and Incidence and Severity of Treatment Emergent Adverse Events up to 2 years. Started Jul 2023; status: terminated.
02
Drugs
XmAb662
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05996445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996445.